Kornimate/medical-research-clean huggingface dataset:
dutch multidomain lifestyle intervention in older adults at risk of cognitive decline

Conditions: Cognitive Decline; Life Style; Risk Reduction

Summary: finger-nl is a multi-center, randomized, controlled, multidomain lifestyle intervention trial among 1,206 older adults at risk for cognitive decline with a duration of 24 months. participants are randomized in a 1:1 ratio to a personalized multi-domain lifestyle intervention (high-intensity intervention group) versus online access to general lifestyle-related health information (low-intensity intervention group). after the intervention period, participants are invited for a 24 month extension of follow-up.


Eligibility criteria:
inclusion criteria: * 60-79 years of age at pre-screening; * adequate fluency in dutch to understand the informed consent and complete questionnaires; * providing informed consent to all study procedures; * internet access at home; * presence of ≥3 self-reported risk factors for cognitive decline (must contain at least 2 modifiable risk factors and 1 non-modifiable riskfactor). exclusion criteria: * diagnosis of dementia or mild cognitive impairment at baseline (self-reported); * significant cognitive impairment assessed using the modified telephone interview for cognitive status battery (ticsm score\<23); * conditions affecting safe and continuous engagement in the intervention (e.g. under treatment for current malignant diseases, major psychiatric disorders (e.g. major depression, psychosis, bipolar disorder), neurological disorders (e.g. parkinson's disease, multiple sclerosis), symptomatic cardiovascular disease (e.g. stroke, angina pectoris, heart failure, myocardial infarction), re-vascularization within three months, severe loss of vision, hearing or communicative ability, severe mobility impairment, other conditions preventing co-operation) as judged by the local study nurse or consulted physician at the local study site; * coincident participation in any other intervention trial at time of pre-screening. * coincident participation of spouse in finger-nl trial.
loco-regional complications of pharyngitis in children: a national case-control study

Conditions: Pharyngitis

Summary: to study the association between several exposures of interest and the occurrence of infectious loco-regional complications of pharyngitis in children.

investigators will include in the study (after agreement of child and parents): * cases: children \< 18 years old hospitalized for peripharyngeal suppurations, diffuse cervical cellulitis or cervical adenophlegmon in participating ear, nose \& throat (ent) and pediatric departments. * controls: children \< 18 years old with pharyngitis but without infectious complications recruited by general practitioners (gps) or by primary care pediatricians in private setting, matched to cases by age, date of infectious complication (index date), delay between the pharyngitis and the index date and, if possible, the referring physician. primary endpoint: difference in the frequency of exposure to various factors among cases and controls during an exposure window going from the date of diagnosis of pharyngitis to day -0.5 of the index date of the complication. several exposure of interest will be compared between cases and controls. one specific main exposure of interest during a predefined window of exposure has been defined but will not be revealed to investigators to avoid selection bias. several secondary exposure of interest were a priori defined but will not be revealed to investigators to avoid selection bias.

Eligibility criteria:
inclusion criteria: cases: children \< 18 years old hospitalized for peripharyngeal suppurations, diffuse cervical cellulitis or cervical adenophlegmon in participating ear, nose \& throat (ent) and pediatric departments. controls: children \< 18 years old with pharyngitis but without infectious complications recruited by general practitioners (gps) or by primary care pediatricians in private setting, matched to cases by age, date of infectious complication (index date), delay between the pharyngitis and the index date and, if possible, the referring physician. exclusion criteria: children (cases or controls) with chronic renal failure, hemophilia, chronic thrombocytopenia or immunosuppression (constitutional or iatrogenic) at the time of pharyngitis

Keywords: pharyngitis case-control study loco-regional complications of pharyngitis
marginal fit of porcelain veneers after finishing prepared surfaces with ultrasonic tips

Conditions: Tooth Discoloration

Summary: the aim of the study is to assess the marginal fit following preparation finishing with ultrasonic tips of porcelain veneers compared to the ordinary preparation using burs only. two-hundred and forty crowns prepared to receive porcelain veneers (in a split-mouth design). on one side of the mouth, the prepared surfaces will be finished with ultrasonic tips. marginal fit is measured by a 'cement replica technique'.

all-ceramic restoration are increasing in daily routine treatments although remain less popular than metal-ceramic crowns especially as the cost of metal rises and aesthetic requested people increases the increased demand for aesthetic treatments has led to the widespread use of metal-free ceramics for conservative restorations. whilst studies for clinical porcelain restorations clarifies satisfactory success rates describes the reasons for failure is due to advance the techniques and materials used in dental restorations. all-ceramic restorations failures are due to several reasons, such as restoration fractures, discoloration in marginal area, marginal misfits and secondary decays. however, secondary caries is the main failure mentioned by the studies, responsible for 21% of the suddenly crown replacements. the etiology of secondary caries is as classified to primary caries, with the involvement of the same cariogenic microorganisms. the place and spread where to invade of primary and secondary lesions are also similar, with secondary caries developing mainly in the gingival tooth interface of restored teeth. different authors have mentioned different instrumentation to prepare teeth appropriately.preparation may be applied using diamond burs attached to sonic devices or high-speed rotating instruments with diamond or tungsten carbide burs. the action of conventional high-speed instruments applied for tooth preparation has been widely researched as well as the adhesion strengths and marginal microleakage it produces. some authors insisted that dental surface morphology of prepared teeth is influenced by the type of bur used for preparation.

Eligibility criteria:
inclusion criteria: * aesthetic requirement with no cracks and congenital loss of any incisors. * discolored teeth not responding to bleaching. exclusion criteria: * evidence proximal caries , * edge to edge occlusion * parafunctional habits * root canal treated teeth.

Keywords: tooth preparation prosthodontics
ultra-low dose bevacizumab plus temozolomide for recurrent high-grade gliomas

Conditions: Recurrent High-grade Glioma

Summary: this study is to evaluate the effectiveness of ultra-low dose bevacizumab plus temozolomide for recurrent high-grade gliomas.

this trial is aimed at evaluating the effectiveness of ultra-low dose bevacizumab plus temozolomide for recurrent high-grade gliomas. and, this trial is approved by medical ethics committee of hebei yanda hospital.researchers will conduct thsi trial from 2015/05 to 2018/05, and 30 recurrent high-grade glioma patients will be recruited. patients who are recruited will get treatment of ultra-low dose bevacizumab plus temozolomide in ether hebei yanda hospital or beijing tiantan hospital, and get follow-ups from clinicians.

Eligibility criteria:
inclusion criteria: * high grade glioma was diagnosed by post-operation pathological method, and shows a relapse. * before included, the patient needs imageological examinations, and the diameter of contrast enhancing area is bigger than 1cm, pet or mrs results show positive features. * the age of patient should be between 18 years old and 70 years old. * the condition of the patient permits the treatment of ultra-low dose bevacizumab plus temozolomide. * the patient is informed consent,and willing to join in this research. exclusion criteria: * the diagnosis is not recurrent high-grade glioma. * the diagnosis of high-grade glioma was not established by pathological method. * the results of imageological examinations do not meet the standard of including. * the age of the patient does not meet the requirement of this research. * the condition of the patient does not permit the treatment of ultra-low dose bevacizumab plus temozolomide. * there are other conditions that the clinicians believe that the treatment of ultra-low dose bevacizumab plus temozolomide is not appropriate for the patient. * the patient is not willing to join in this research.

Keywords: glioma high-grade glioma
a single patient compassionate use of mbm-02 (tempol) for the treatment of prostate cancer

Conditions: Prostate Cancer

Summary: a single patient compassionate use clinical trial for the use of mbm-02 (tempol) for the treatment of prostate cancer. the single patient will be exposed to orally administered tempol for up to 12 months at a maximum total daily dose of 800mg.

localized therapy for prostate cancer is often curative; however, 20% to 30% of patients experience a recurrence. biochemical recurrence (bcr) occurs in an estimated 50,000 men/year in the u.s and is marked by a rising prostate specific antigen (psa) after definitive radical prostatectomy and/or radiation therapy for localized disease. continuous androgen deprivation therapy (adt), in which serum testosterone is decreased to a castrate level (less than 50 ng/dl) is a standard treatment in bcr. adt is associated with significant short term and long term toxicities, including declining quality of life on treatment and increased risk of osteoporosis, diabetes, and cardiovascular disease. mbm-02 is being tested as a novel non-hormonal agent with improved biologic activity and better tolerability for use in biochemically recurrent prostate cancer.

Eligibility criteria:
inclusion criteria: * biochemical recurrent prostate cancer exclusion criteria: -
safety and iop-lowering effects of wb007

Conditions: Glaucoma, Primary Open Angle; Ocular Hypertension

Summary: the study evaluated the safety and iop-lowering effects of wb007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. this was a 2-part study. part 1 was a 3-period dose escalation that evaluated 3 concentrations of wb007 ophthalmic solution following a single dose in one eye. part 2 was a randomized, double-masked, parallel comparison that evaluated two concentrations of wb007 (selected based on part 1 results) in both eyes compared with timolol 0.5% for 14 days.


Eligibility criteria:
inclusion criteria: * ocular hypertension or primary open-angle glaucoma in each eye exclusion criteria: * history of orthostatic hypotension * any active ocular disease * anticipated wearing of contact lenses during study * contraindication to pupil dilatation

Keywords: poag oht primary open-angle glaucoma ocular hypertension
methylprednisolone pulse macrolide therapy for refractory mycoplasma pneumoniae pneumonia in children

Conditions: Refractory Mycoplasma Pneumoniae Pneumonia

Summary: the purpose of this study is planned to investigate whether small doses of methylprednisolone pulse macrolide therapy can relieve symptoms,chest x-rays faster than macrolide alone therapy for refractory mycoplasma pneumoniae pneumonia(mpp) .

corticosteroid has been used in adulthood refractory mpp with satisfactory efficacy. but there were few studies about the use of corticosteroid in children with refractory mpp. lee ky et al indicated oral prednisolone of 1 mg/kg/ day for 1 week be useful for children with severe mpp. akihiro t et al demonstrated that intravenously administered methylprednisolone at a dose of 30 mg/kg once daily for 3 consecutive days had an efficacious treatment for children with refractory mpp.but the methods of corticosteroid use, such as the dosage, administration route, duration of treatment have not been well understood. so in this study, we planned to investigate whether small doses of methylprednisolone pulse macrolide therapy can relieve symptoms,chest x-rays faster than macrolide alone therapy for refractory mycoplasma pneumoniae pneumonia in a prospective, open-label fashion. pmid: 11096025 pmid: 18033831 pmid: 10434547 pmid: 16437541 pmid: 18656264

Eligibility criteria:
inclusion criteria: * mycoplasma pneumoniae pneumonia * prolonged fever and deterioration of radiological findings despite macrolides treatment for 7 days or more. exclusion criteria: * chronic cardiac and pulmonary disease * immunodeficiency * requiring mechanical ventilation * with other pathogens detected during pneumonia.

Keywords: refractory mycoplasma pneumoniae pneumonia
cardiovascular oscillations in coronary patients with and without type 2 diabetes

Conditions: Coronary Artery Disease; Diabetes Mellitus, Type 2

Summary: coronary artery disease (cad) and diabetes mellitus (dm) may promote alterations in heart responses during exercise or postural maneuver. thus, the purpose of this study is to observe the influence of different postures (supine, seated and standing) and different percentages (15, 30, 45 and 60%) of the maximum voluntary contraction (mvc) of handgrip in the responses of heart rate (hr), systolic blood pressure (sbp), diastolic blood pressure (dbp), mean arterial pressure (map), cardiac output (co), stroke volume (sv) and peripheral vascular resistance (pvr) in coronary patients with and without type 2 diabetes.


Eligibility criteria:
inclusion criteria: * coronary artery disease * clinical diagnosis of type 2 diabetes * free of type 2 diabetes to participate of control group and coronary disease without type 2 diabetes group * nonsmokers * not alcoholics exclusion criteria: * autonomic neuropathy * clinical exercise testing with ecg alterations (st-segment depression greater than 2 mm, ventricular and supraventricular arrhythmias, sustained or non-sustained supraventricular tachycardia, atrial tachycardia, atrial fibrillation and atrioventricular blocks) or symptom of angina induced by stress. * individuals with hypertension and diabetes mellitus not controlled. * subjects who did not complete all assessments. * subjects with temporal (r-ri and pressure) series with noise preventing the evaluation

Keywords: isometric exercise arterial pressure autonomic nervous system cardiovascular system posture
anxiety reduction during office procedural medicine using aromatherapy

Conditions: Anxiety; Anxiety State; Procedural Anxiety

Summary: this goal of this study is to assess whether lavender aromatherapy during gynecologic and urogynecologic outpatient procedures is associated with a decrease in patient anxiety levels. based on similar interventions in other specialties of medicine, the investigators hypothesize that patients exposed to lavender aromatherapy during their procedure will have less anxiety than those who are not exposed to lavender aromatherapy.

patients who present to the loyola urogynecology office for an outpatient procedure will be invited to participate. patients who consent to participate will be asked to complete pre-procedure questionnaires including an assessment of their level of procedural anxiety. subsequently, patients will be randomized to receive either lavender aromatherapy or saline aromatherapy (placebo) during their procedure. post-procedural levels of anxiety will then be assessed. changes between pre- and post-procedural anxiety will be compared between the treatment and placebo control groups.

Eligibility criteria:
inclusion criteria: * women undergoing the following gynecologic/urogynecologic office procedures: colposcopy, loop electrical excision procedure (leep), endometrial biopsy, intrauterine device (iud) insertion, hysteroscopy, nexplanon removal, cystoscopy, urodynamics, botox intravesical injection, and transurethral bulking injection * english speaking * ability to complete questionnaires exclusion criteria: * pregnancy * allergy to lavender scent * lung disease including asthma or chronic lung disease * anosmia or problems related to smell * chronic headaches or migraines * inability to complete questionnaires
probiotic bl ncc 2705 and gluten sensitivity

Conditions: Celiac Disease; Non-celiac Gluten Sensitivity

Summary: the aim of the study is to confirm/prove safety of the probiotic and production of serpin in humans.

this trial is a multicenter, double blind, randomized, placebo controlled, 2 by 2 cross-over design (i.e. 2-sequences, 2-periods, 2-treatments) for each specific population (i.e. self-reported non coeliac gluten sensitivity and coeliac disease subjects). 1 capsule of bl ncc 2705 or placebo will be given twice a day in the morning and in the evening with a meal over 2 periods of 4 days. on day four a single dose of gluten (3g) will be administered and duodenal fluid will be collected in the following hours through a naso-intestinal catheter. the viability of bl ncc 2705, the production of serpin and its effects on gluten digestion and intestinal enzymatic activity will be determined. no chronic administration of gluten as a challenge is foreseen in the study. after a wash out period of minimum 2 weeks, period will be repeated.

Eligibility criteria:
inclusion criteria: 1. willing and able to sign written informed consent prior to trial entry 2. male or female adults \>18 years of age 3. for ncgs: self-reported gluten sensitivity with negative cd serology, on gluten free diet for at least 6 weeks with self-reported significant symptomatic improvement 4. for cd: confirmed serologic and histologic diagnosis of cd and on gfd for at least 12 months with self-reported significant symptomatic improvement 5. body mass index (bmi) within the range \>18 - \<30 kg/m2 6. willing and able to comply with study procedures and restrictions 7. in good health as determined by a medical history and medical examination exclusion criteria: 1. documented ige-mediated food allergy 2. subjects following an overly imbalanced or restrictive diet as per nutritional advice 3. concurrent systemic disease and/or laboratory abnormalities considered by investigators to be detrimental for the participants safety or potentially interfering with the study procedures and/or study outcomes 4. concurrent organic gi pathology other than benign polyps, diverticulosis, hemorrhoids, lipomas and melanosis coli 5. previous abdominal surgery with the exception of hernia repair, appendectomy, caesarian section, tubal ligation, hysterectomy, hemorrhoidectomy 6. patients who received antibiotics in the previous 2 weeks 7. women of childbearing potential not willing to use an effective contraception method
rd13-01 for patients with r/r cd7+ t/nk cell hematologic malignancies

Conditions: Hematologic Malignancies

Summary: this study is designed to explore the safety of rd13-01 for patients with cd7+ relapsed and/or refractory t/nk-cell hematologic malignancies. and to evaluate the efficacy and pharmacokinetics of rd13-01 in patients.


Eligibility criteria:
inclusion criteria: 1. aged 3 to 70 years. 2. diagnosis of r/r t-all/nk-all, t-lbl, or t-nhl (including ptcl-nos, aitl, alcl, extranodal nk/t cell lymphoma). 3. ecog: 0-2. 4. life expectancy greater than 12 weeks. 5. cardiac left ventricle ejection fraction ≥50%. 6. informed consent explained to, understood by and signed by the patient/guardian. patient/guardian is given a copy of informed consent. exclusion criteria: 1. pregnant or lactating. 2. hepatitis b surface antigen (hbsag) or hepatitis b core antibody (hbcab) positive and peripheral blood hepatitis b virus (hbv) dna titer detection is not within the normal range; hepatitis c virus (hcv) antibody positive and peripheral blood hepatitis c viral (hcv) rna positive; human immunodeficiency virus (hiv) antibody positive; cytomegalovirus (cmv) dna positive; syphilis positive. 3. patients with graft-versus-host disease (gvhd) or who need to use immunosuppressive drugs. 4. participated in other clinical studies within 2 weeks prior to screening. 5. history of alcoholism, drug abuse or mental illness. 6. any situations that the investigator believes may increase the risk of patients or interfere with the results of study.
smart phone application for enteral nutrition

Conditions: Nutritional and Metabolic Diseases

Summary: internal medicine resident physicians were provided an ipod with the en application to assist them in choosing en formulas for patients during their icu rotation. the primary outcome was improved initiation of en within 24 hours of admission. secondary outcomes include, time to initiate en, goal calories reached, infections rates, length of stay, mortality, and concordance with clinical guidelines.

background: resident physicians are frequently uncomfortable ordering enteral nutrition (en) and are unaware of the variety of formulas and supplements available for different disease processes. many depend on a clinical dietitian to assist with recommending en formulas and patient energy requirements which may not be readily available upon patient admission. this creates a barrier to early initiation of en and non-compliance with society of critical care medicine and american society of parenteral and enteral nutrition clinical guidelines. objective: internal medicine resident physicians were provided an ipod with the en application to assist them in choosing en formulas for patients during their icu rotation. the primary outcome was improved initiation of en within 24 hours of admission. secondary outcomes include, time to initiate en, goal calories reached. design: this study is a retrospective chart review to evaluate the impact of a smart phone/device application (en application) to assist resident physicians when ordering en. the study is a single center trial conducted at an academic teaching facility. all patient data was obtained by a retrospective chart review of patients admitted to the intensive care unit (icu) at the university of oklahoma medical center.

Eligibility criteria:
inclusion criteria: 1. admitted to the icu 2. require mechanical ventilation 3. physician plans to order enteral nutrition for the patient exclusion criteria: 1. death likely within 24 hours 2. needing parenteral nutrition 3. cannot tolerate enteral nutrition for any reason
safety and efficacy study to treat bacterial vaginosis

Conditions: Bacterial Vaginosis

Summary: the purpose of this study is to determine if product 55394 is safe and efficacious for the treatment of bacterial vaginosis.


Eligibility criteria:
inclusion criteria: * have a clinical diagnosis of bacterial vaginosis as determined by the investigator. * other items as identified in the protocol. exclusion criteria: * have a known or suspected other infectious cause of vulvovaginitis. * other items as identified in the protocol.